Bristol-Myers Squibb Company
A biopharmaceutical company that discovers and sells medicines for cancer, heart, immune, and brain conditions, with well-known brands like the immunotherapy Opdivo, the blood thinner Eliquis, and the cell therapy Breyanzi. It was formed in 1989 when two old American drugmakers merged: Bristol-Myers, started in 1887 by two college friends who bought a struggling New York firm, and Squibb, founded in 1858 by a doctor who supplied the Union Army during the Civil War. A fun early hit for the Bristol-Myers side was Sal Hepatica, a mineral-salt laxative meant to mimic natural mineral waters.
Granted 95.5K
Granted 190.1K
Granted 194.8K · Bought 7.1K
Granted 205.6K · Sold 86.0K
Granted 82.5K · Bought 7.9K
Granted 57.1K
Bought 8.5K
Granted 38.5K
Granted 20.5K
Granted 62.1K
Granted 26.7K · Sold 97.39
Granted 63.0K
Granted 28.6K
Granted 18.9K · Sold 1.2K
Granted 23.9K · Sold 378
Granted 19.1K
Granted 20.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Leung SandraEVP, General Counsel · 23 transactions | — | 455.5Kas of Mar 2025 | 95.5K | — | — |
| Caforio GiovanniExecutive Chair of the Board, Director · 10 transactions | +32.9% | 386.8Kas of Mar 2024 | 190.1K | — | — |
| Boerner Christopher S.Chief Executive Officer, Director · 48 transactions | — | 261.7K | 194.8K | 7.1K | — |
| Elkins David VEVP, Chief Financial Officer · 35 transactions | +13% | 159.5K | 205.6K | — | 86.0K |
| Hirawat SamitEVP,Chief Med.Offr.,Drug Dev. · 24 transactions | +76.8% | 83.5Kas of Apr 2025 | 82.5K | 7.9K | — |
| Lenkowsky AdamEVP, Chief Commercial Officer · 36 transactions | — | 46.8K | 57.1K | — | — |
| Samuels Theodore R. IIDirector · 1 transaction | +28.7% | 38.1Kas of Nov 2023 | — | 8.5K | — |
| Plenge Robert MEVP, Chief Research Officer · 32 transactions | — | 34.8K | 38.5K | — | — |
| Haller Julia ADirector · 1 transaction | +150.2% | 34.1K | 20.5K | — | — |
| Shanahan KarinEVP, Chief Supply Chain & Ops · 26 transactions | +588.2% | 27.3K | 62.1K | — | — |
| Hickey BenjaminPresident, RayzeBio Org. · 9 transactions | — | 25.6K | 26.7K | — | 97.39 |
| Meyers Gregory ScottEVP, Chief Digital & Tech Off. · 26 transactions | +602.6% | 24.6K | 63.0K | — | — |
| Gallman CariEVP, General Counsel · 38 transactions | — | 17.0K | 28.6K | — | — |
| Holzer Phil MSVP and Controller · 32 transactions | — | 16.9K | 18.9K | — | 1.2K |
| Short Bartie WendyEVP, Corporate Affairs · 17 transactions | — | 16.0K | 23.9K | — | 378 |
| Poole Ahn AmandaEVP, Chief People Officer · 30 transactions | — | 6.1K | 19.1K | — | — |
| Hoch LynellePresident, Cell Therapy Org. · 30 transactions | — | 5.9K | 20.0K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: -64.2K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.